Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Alkylating agent (nitrogen mustard)
Mechlorethamine
Mustargen · MECH
Prototype nitrogen mustard alkylator whose renal relevance is tumor lysis in bulky lymphoma; the modern topical gel has no detectable systemic absorption.
Moderateearly-cytotoxic · approved 1949
Hodgkin lymphoma (historically as the M in MOPP)Non-Hodgkin lymphomaMycosis fungoides / cutaneous T-cell lymphoma (topical gel)Malignant pleural and pericardial effusions (intracavitary, historical)
Signature kidney injury
Electrolyte Wasting
Direct nephrotoxicity is not a defining feature. The principal renal hazard is tumor lysis syndrome when treating bulky, rapidly proliferating lymphoma; incidence specifically attributable to mechlorethamine is not quantified because it is used within multi-agent regimens. The 0.016%/0.02% topical gel shows no detectable systemic absorption.
Source: Lessin et al., JAMA Dermatol 2013 (topical gel: no detectable systemic absorption)
Mechanism of kidney injury
As a class alkylator, systemic mechlorethamine can contribute to tumor lysis in chemosensitive bulky disease, with uric-acid and phosphate intratubular precipitation and AKI. A direct tubular (ATN-type) insult is conceivable for a highly reactive alkylating agent but is not a well-characterized clinical signature. Topically applied gel does not reach the systemic circulation in measurable amounts, so renal exposure from the dermatologic formulation is negligible.
Clinical presentation
When TLS occurs, hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and rising creatinine shortly after starting therapy. No characteristic urinary syndrome is attributed to the drug itself; topical use is associated with skin irritation rather than kidney effects.
Onset
TLS within hours to days of effective cytoreduction in bulky lymphoma.
Reversibility
Reversible
Anticancer mechanism
Highly reactive bifunctional nitrogen mustard that forms an aziridinium ion and crosslinks DNA (predominantly at the N7 of guanine), producing interstrand and intrastrand crosslinks that block replication and trigger apoptosis.
Management
Treat TLS with hydration, uric-acid-lowering therapy, electrolyte correction and dialysis if refractory. There is no specific antidote for mechlorethamine renal effects; supportive care and good hydration are the mainstays. Topical exposures require only local skin care.
Risk factors
- High tumor burden / bulky chemosensitive lymphoma
- Elevated baseline uric acid or LDH
- Volume depletion and pre-existing CKD
- Inadequate hydration or uric-acid prophylaxis
Prevention
- TLS risk stratification before treating bulky disease
- IV hydration
- Allopurinol or rasburicase per risk
- Electrolyte monitoring during initial cycles
- Prefer topical route for limited cutaneous disease where systemic exposure is unnecessary
Note · Systemic mechlorethamine is largely of historical interest (MOPP), now supplanted by ABVD and other regimens; the contemporary product in wide use is the topical gel for mycosis fungoides, which carries negligible systemic/renal risk.
Clinical depth
Renal dose adjustment
No validated renal dose-adjustment algorithm for systemic use; the drug is rapidly chemically hydrolyzed with very short plasma half-life. Topical gel requires no renal adjustment given absent systemic absorption.
Dialyzability & ESKD dosing
Not relevant for drug removal given near-instantaneous chemical degradation in plasma; dialysis is used only to manage TLS metabolic complications.
Differential diagnosis
Distinguish TLS-driven AKI from prerenal azotemia and from obstruction by bulky nodal disease. Direct alkylator tubular injury is not a well-established clinical entity for this drug and should be a diagnosis of exclusion.
Monitoring
- Serum creatinine, potassium, phosphate, calcium and uric acid during initial cytoreduction
- CBC
- Urine output and volume status
- (Topical) local skin reactions rather than renal labs
Key trials & series
- MOPP-era Hodgkin lymphoma regimens establishing mechlorethamine as a systemic alkylator (regimen-level evidence)
- Randomized multicenter trial of mechlorethamine 0.02% gel in mycosis fungoides demonstrating efficacy with no detectable systemic absorption (PMID 23069814)
Clinical pearls
- For systemic nitrogen mustard, the kidney is threatened mainly through tumor lysis in bulky lymphoma, not through a characteristic intrinsic nephrotoxicity.
- The topical mechlorethamine gel has no detectable systemic absorption and therefore essentially no renal risk.
- Hydration and uric-acid prophylaxis remain the key kidney-protective steps when treating bulky chemosensitive disease.
Where it strikes
Nephron segments
Tubular Lumen
The urine flow path
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Electrolyte WastingAcute Tubular Necrosis
Beyond the kidney
Class-level context for the major non-renal toxicities of alkylating agent (nitrogen mustard)s.
Ophthalmic
Keratopathy, uveitis, retinopathy
- Visual disturbance (crizotinib)
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- CNS effects (lorlatinib)
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTopical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.Lessin SR et al. · JAMA Dermatol 2013 · PMID 23069814Pivotal randomized trial of topical mechlorethamine gel reporting no detected systemic absorption, supporting negligible systemic/renal exposure from the dermatologic formulation.PMIDLack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.Querfeld C et al. · J Invest Dermatol 2021 · PMID 33347924Pharmacokinetic analysis confirming absence of systemic absorption of topical mechlorethamine gel, reinforcing minimal systemic/renal exposure.LandmarkThe tumor lysis syndrome.Howard SC et al. · N Engl J Med 2011 · PMID 21561350Review of tumor lysis syndrome relevant to treating bulky chemosensitive lymphoma with alkylator-based regimens.LandmarkConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology review of kidney complications of conventional cytotoxic chemotherapy, including alkylating-agent class effects and electrolyte disturbances.